News | June 10, 2024
Neuland unveils refreshed brand identity
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Establishing Asymchem’s first manufacturing footprint in Europe
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Subscribe To Our Newsletter & Stay Updated
